Insmed, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4576693075
USD
143.85
3.72 (2.65%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Apellis Pharmaceuticals, Inc.
Exelixis, Inc.
Alkermes Plc
Insmed, Inc.
Intra-Cellular Therapies, Inc.
Perrigo Co. Plc
Jazz Pharmaceuticals Plc
Ionis Pharmaceuticals, Inc.
Catalent, Inc.
Organon & Co.
Karuna Therapeutics, Inc.

Why is Insmed, Inc. ?

1
  • NET PROFIT(HY) Higher at USD -523.81 MM
  • INVENTORY TURNOVER RATIO(HY) Highest at 1.12 times
  • RAW MATERIAL COST(Y) Fallen by -12.04% (YoY)
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 91.12%, its profits have fallen by -38.4%
3
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Consistent Returns over the last 3 years
  • Along with generating 91.12% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Insmed, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Insmed, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Insmed, Inc.
92.08%
2.65
52.36%
S&P 500
17.78%
0.92
19.35%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
29.83%
EBIT Growth (5y)
-211.85%
EBIT to Interest (avg)
-10.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.79
Sales to Capital Employed (avg)
0.28
Tax Ratio
0.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
28.40
EV to EBIT
-37.03
EV to EBITDA
-37.53
EV to Capital Employed
324.13
EV to Sales
86.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-875.41%
ROE (Latest)
-76.35%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company
NET PROFIT(HY)

Higher at USD -523.81 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.12 times

RAW MATERIAL COST(Y)

Fallen by -12.04% (YoY

CASH AND EQV(HY)

Highest at USD 3,110.03 MM

NET SALES(Q)

Highest at USD 263.84 MM

OPERATING PROFIT MARGIN(Q)

Highest at -92.53 %

-6What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -935.02 MM

ROCE(HY)

Lowest at -249.28%

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.29 times

Here's what is working for Insmed, Inc.

Net Sales
At USD 263.84 MM has Grown at 136.09%
over average net sales of the previous four periods of USD 111.76 MM
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Net Profit
Higher at USD -523.81 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Inventory Turnover Ratio
Highest at 1.12 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales
Highest at USD 263.84 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit Margin
Highest at -92.53 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Cash and Eqv
Highest at USD 3,110.03 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by -12.04% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 5.56 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation
At USD 5.56 MM has Grown at 39.16%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Insmed, Inc.

Operating Cash Flow
Lowest at USD -935.02 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debtors Turnover Ratio
Lowest at 6.29 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio